UST OF REFERENCES CITED BY APPLICANTS
(Use several sheets if necessary)

_	ATTY, DOCKET NO.	APPLICATION NO			
	2254-031-0	09/644.456			
	APPLICANT				
	HORNIK et al.				
	FRING DATE	CROUP			
	August 24, 2000	16.34			

			U.S	S. PATENT DOCUMENTS		19.59.	
"EXAUMER		DOCUMENT NUMBER	DATE	NAMERECEIVE	P:	SUBCLASS	FENG DATE
my	AA	5,639,455	6/1997	Shimamura et al. OCT 0 2003	424	133.1	
	AB	5.470.942	11/1995	Alexander et al. TECH CENTER 1600/2 Suto et al.	528	328	
	AC	5,420,109	5/1995	Suto et al.	514	8	
m	AD	5,210,075	5/1993	Scholz et al.	514	14	<u> </u>
			FORE	IGN PATENT DOCUMENTS	,	·	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUECLASS	TRANSLATION
m	AE	WO 00/72864 A1	07/2000	PCT			YES NO
1	AF	WO 99/65508	12/1999	PCT			
-i-	AG	WO 98/04583	2/1998	РСТ			
Ť	AH	WO 97/48728	12/1997	PCT			
	A	WO 97/13781	4/1997	PCT			
1 -	AJ.	WO 97/09344	3/1997	РСТ			
1	AK	WO 95/33765	12/1995	PCT			
Aus	AL	WO 95/13086	5/1995	РСТ			
				cluding Author, Title, Date, Pertinent Pages, Etc.)			
My	AM			its Receptor: Ten Years Later", Intern. Rev.	Immuno	ol., 16:249	
1	AN	Yoshizaki et al., 1998, "Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody", Springer Semin. Immunopathol., 20: 247.					
	AO	Kozak et al. 1997 " Sickness Behavior in Mice Deficient in Interleukin-6 During Turpentine Abscess and					
AP Simpson et al., 1997, "Interleukin-6: Structure-function Relationships", Protein Sci., 6: 929.							
AQ Xu et al., 1997, "Solution Structure of Recombinant Human Interleukin-6", J. Mol. Biol., 268: 468.							
1	AR	Fourcip et al. 1996 "ap130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type					
	AS	Murakamin-Mori et al., 1996, "The Soluble Form of the IL-6 Receptor (slL-6Rα) Is a Potent Growth Factor for AIDS-associated Kaposi's sarcoma (KS) cells; the Soluble Form of gp130 Is Antagonistic for slL-6Rα-Induced AIDS-KS Cell Growth", Int. Immunol., 8: 595.					
	АТ	Ogata, A., 1996, "Therapeutic Strategies of Inhibition of Interleukin-6 Mediated Multiple Myeloma Cell Growth", Leuk. Res., 20: 303.					
	AU	Sporeno et al., 1996, "Human Interleukin-6 Receptor Super-Antagonists with High Potency and Wide Spectrum on Multiple Myeloma Cells", Blood, 87: 4510.					
	AV	Toniatti et al., 1996, "Engineering Human Interleukin-6 to Obtain Variants with Strongly Enhanced Bioactivity", The EMBO J., 15: 2726.					
	AW .	Halimi et al., 1995, "Epitope Peptides from Interleukin-6 Receptor Which Inhibit the Growth of Human Myeloma Cells", Eur. Cytokin. Netw., 6: 135.					
UB	AX Klein et al., 1995, "Interleukin-6 in Human Multiple Myeloma", Blood, 85: 863.						

Sheet	1	of	2	

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

#11+ DOC+11+0	Phone 40	2
2254-031		· ~ 集
IM CINI		9.4.3
Vered HORNIK et al.		重要に

1 a mG (30 1 (August 24, 2000 U.S. PATENT DOCUMENTS 0411 MN AA 3,988,304 10/1976 Garsky 260 78A AB 4,011,182 03/1977 Sarantakis 260 8 AC 4,054,558 10/1977 Garsky 260 112.55 AD 4,187,217 02/1980 Chipens et al. 260 112.5R ΑE 4.235.886 11/1980 Freidinger et al. 424 177 AF 4,310,518 01/1982 Freidinger et al. 424 177 AG 5,364,851 11/1994 Joran 530 345 AH 5,371,070 12/1994 Koerber et al. 514 9 ΑI 5,770,687 Hornik et al. 06/1998 530 311 AJ 5,874,529 02/1999 Gilon et a. 530 317 AK 5.883,293 06/1999 Gilon et al. 562 455 Ч'n 6,051,554 04/2000 Hornik et al. 514 11 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER 0411 SUBCI ASS INAME AT COM MM 031 303 07/1981 European Patent Office × AN 334 244 09/1989 **European Patent Office** ΑO 336 779 10/1989 European Patent Office AP 370 453 05/1990 **European Patent Office** X AO 395 417 10/1990 **European Patent Office** AR 564 739 10/1993 European Patent Office AS 2 304 352 10/1976 France × AT 2 411 828 07/1979 France × AU 41 19 544 10/1992 Germany × AV WO 89/01781 03/1989 **WIPO** AW WO 92/00091 01/1992 WIPO ΑX WO 92/22566 12/1992 WIPO AY WO 93/01206 01/1993 **WIPO** ΑZ WO 94/11393 05/1994 WIPO W BA WO 95/01800 01/1995 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) **B**B Bell et al., 1993, "Molecular biology of somatostatin receptors", TINS 16:34-38. Brazeau et al. 1973, "Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone", Science 179:77-79. BC Buscail et al., 1995, "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated mechanisms", Proc. Natl. by somatostatin receptor subtypes SSTR2 and SSTR5

BD is mediated mechanisms*, Proc. Natl. by somato through different Acad. Sci. USA 92:1580-1584.

Ulmi

DATE CONSIDERED

EXAMINER

02/04